Skip to Content

Strs Ohio purchases 32,400 Corcept Therapeutics Incorporated shares (NASDAQ:CORT)

Strs Ohio purchases 32,400 Corcept Therapeutics Incorporated shares (NASDAQ:CORT)

The most recent report that Strs Ohio has submitted to the SEC indicates that the company has increased the proportion of its holdings in Corcept Therapeutics Incorporated (NASDAQ: CORT). The corporation paid approximately $830,000 to acquire all 32,400 stock available in the biotechnology company.

The percentages of CORT shares that other institutional investors own have been rebalanced due to these recalculations. During the first three months of 2018, JPMorgan Chase & Co. increased the total number of shares of Corcept Therapeutics that it owned by 2.4 percent. During the most recent quarter, JPMorgan Chase & Co. increased its holdings in the biotechnology company’s stock by 5,036 shares, bringing the total number of shares it owned to 216,081, with a value of $4,864,000. The value of American Century Companies Inc.’s holdings in Corcept Therapeutics increased by 8.2 percent during the first three months of 2018. Following the acquisition of a further 6,684 shares during the most recent quarter, American Century Companies Inc. now possesses a total of 88,553 shares of the stock held by the biotechnology company. These shares are currently valued at $1,994,000 due to their combined value. The increase in the number of shares that Citigroup Inc. held in Corcept Therapeutics during the first quarter was equal to 15.0% of the total number of shares held. Because of the purchase of 13,488 additional shares during the most recent quarter, Citigroup Inc. now has 103,241 shares in the biotechnology business. These shares are currently valued at a total of $2,325,000. Through the first three months of 2018, Natixis Advisors L.P. achieved a 56.7% increase in the proportion of its holdings invested in Corcept Therapeutics. After purchasing 6,726 additional shares during the most recent quarter, Natixis Advisors L.P. now owns a total of 18,581 shares in the biotechnology company. The value of these shares is $418,000 if we use today’s closing price as our benchmark (as of the previous trading day). And finally, during the first three months of this year, Acadian Asset Management LLC added 3.3% more shares of Corcept Therapeutics Inc. stock to its holdings, bringing the total number of shares it possessed to 14. Following the acquisition of an additional 1,032 shares during the most recent fiscal quarter, Acadian Asset Management LLC now holds a total of 31,845 shares of the biotechnology company’s stock. Acadian Asset Management LLC’s stock holdings in the biotechnology company have a total

Tags

Leave a comment

Your email address will not be published. Required fields are marked *